Determination of amino acids in urine of patients with prostate cancer and benign prostate growth

European Journal of Cancer Prevention

Volumn 26, Issue 2, 2017, Pages 131-134

  Sroka, Wiktor D ^a   Boughton, Berin A ^d   Reddy, Priyanka ^d   Roessner, Ute ^d   Słupski, Piotr ^b   Jarzemski, Piotr ^b   Dąbrowska, Anita ^a   Markuszewski, Michał J ^c   Marszałł, Michał P ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

amino acids; benign prostatic hyperplasia; biomarker; cancer; prostate

Indexed keywords

ALANINE; AMINE; AMINO ACID; ARGININE; ASPARTIC ACID; BETA ALANINE; CITRULLINE; CYSTEINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HOMOSERINE; ISOLEUCINE; KYNURENINE; LEUCINE; LYSINE; METHIONINE; ORNITHINE; PHENYLALANINE; PROLINE; PUTRESCINE; SARCOSINE; SERINE; TAURINE; THREONINE; TRYPTOPHAN; TYRAMINE; TYROSINE; VALINE; TUMOR MARKER;

AMINO ACID ANALYSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; DISEASE MARKER; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; URINALYSIS; URINE SAMPLING; PROSTATE TUMOR; URINE;

AMINO ACIDS; BIOMARKERS, TUMOR; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84969930951     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000248     Document Type: Article

References (9)

1. Birkemeyer C, Luedemann A, Wagner C, Erban A, Kopka J (2005). Metabolome analysis: the potential of in vivo labeling with stable isotopes for metabolite profiling. Trends Biotechnol 23:28-33.
2. Boughton BA, Callahan DL, Silva C, Bowne J, Nahid A, Rupasinghe T, et al. (2011). Comprehensive profiling and quantitation of amine group containing metabolites. Anal Chem 83:7523-7530.
3. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. (2006). Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66:10795-10804.
4. Lilja H, Ulmert D, Vickers AJ (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8:268-278.
5. Marszailil MP, Sroka W, Adamowski M, Silupski P, Jarzemski P, Siódmiak J, Odrowaz-Sypniewska G (2015). Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination. Eur J Cancer Prev 24:51-56.
6. Serkova NJ, Standiford TJ, Stringer KA (2011). The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. Am J Respir Crit Care Med 184:647-655.
7. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914.
8. Wang H, Tso VK, Slupsky CM, Fedorak RN (2010). Metabolomics and detection of colorectal cancer in humans: a systematic review. Future Oncol 6:1395-1406.
9. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. (2010). American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70-98.